Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Inovio Pharmaceuticals Inc (NASDAQ:INO)

7.08
Delayed Data
As of Dec 05
 +0.22 / +3.21%
Today’s Change
4.50
Today|||52-Week Range
11.69
+5.36%
Year-to-Date
Inovio Pharmaceuticals' Next Zika Opportunity
Dec 01 / MotleyFool.com - Paid Partner Content
Is This Drug Inovio Pharmaceuticals' Best Chance for Success?
Nov 22 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close6.86
Today’s open7.02
Day’s range6.89 - 7.25
Volume1,089,259
Average volume (3 months)1,196,648
Market cap$508.1M
Dividend yield--
Data as of 3:59pm ET, 12/05/2016

Growth & Valuation

Earnings growth (last year)+31.25%
Earnings growth (this year)--
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+288.00%
P/E ratioNM
Price/Sales11.32
Price/Book2.82

Competitors

 Today’s
change
Today’s
% change
RVNCRevance Therapeutics...+0.05+0.28%
SCLNSciClone Pharmaceuti...+0.15+1.48%
MYOKMyoKardia Inc-0.20-1.21%
COLLCollegium Pharmaceut...-0.43-2.56%
Data as of 3:59pm ET, 12/05/2016

Financials

Next reporting dateMarch 20, 2017
EPS forecast (this quarter)-$0.31
Annual revenue (last year)$40.6M
Annual profit (last year)-$29.2M
Net profit margin-71.94%

Profile

Sector
Health Technology
Industry
Medical Specialties
President, Chief Executive Officer &
Director
J. Joseph Kim
Chief Operating Officer
Niranjan Y. Sardesai
Corporate headquarters
Plymouth Meeting, Pennsylvania

Forecasts


Search for Jobs